このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

CardieX 将来の成長

Future 基準チェック /56

CardieXは、114.3%と63.7%でそれぞれ年率114.3%で利益と収益が成長すると予測される一方、EPSはgrowで122.1%年率。

主要情報

115.3%

収益成長率

122.1%

EPS成長率

Medical Equipment 収益成長	17.0%
収益成長率	62.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	19 Jun 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

ASX:CDX - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2026	52	24	24	24	1
6/30/2025	18	-3	-3	-3	1
6/30/2024	12	-8	-11	-11	1
12/31/2023	14	-9	-5	-5	N/A
9/30/2023	10	-14	-9	-9	N/A
6/30/2023	6	-19	-12	-12	N/A
3/31/2023	5	-16	-11	-11	N/A
12/31/2022	4	-14	-10	-10	N/A
9/30/2022	4	-13	-10	-9	N/A
6/30/2022	5	-12	-10	-9	N/A
3/31/2022	5	-11	-9	-8	N/A
12/31/2021	5	-10	-8	-8	N/A
9/30/2021	5	-7	-6	-6	N/A
6/30/2021	6	-5	-4	-4	N/A
3/31/2021	5	-4	-3	-3	N/A
12/31/2020	5	-3	-2	-2	N/A
9/30/2020	5	-3	-2	-2	N/A
6/30/2020	5	-3	-2	-2	N/A
3/31/2020	5	-3	-2	-2	N/A
12/31/2019	5	-4	-2	-2	N/A
9/30/2019	5	-3	-2	-2	N/A
6/30/2019	5	-3	-3	-2	N/A
3/31/2019	5	-3	-3	-3	N/A
12/31/2018	4	-3	-3	-3	N/A
9/30/2018	4	-3	-2	-2	N/A
6/30/2018	4	-3	-2	-2	N/A
3/31/2018	5	-3	-2	-2	N/A
12/31/2017	5	-4	-2	-2	N/A
9/30/2017	5	-4	N/A	-3	N/A
6/30/2017	5	-4	N/A	-3	N/A
3/31/2017	5	-4	N/A	-4	N/A
12/31/2016	5	-4	N/A	-4	N/A
9/30/2016	5	-5	N/A	-5	N/A
6/30/2016	5	-5	N/A	-5	N/A
3/31/2016	5	-4	N/A	-4	N/A
12/31/2015	4	-4	N/A	-4	N/A
9/30/2015	5	-3	N/A	-3	N/A
6/30/2015	5	-1	N/A	-2	N/A
3/31/2015	5	-2	N/A	-2	N/A
12/31/2014	5	-2	N/A	-3	N/A
9/30/2014	5	-2	N/A	-2	N/A
6/30/2014	5	-3	N/A	-1	N/A
3/31/2014	6	-2	N/A	0	N/A
12/31/2013	6	0	N/A	1	N/A
9/30/2013	8	1	N/A	1	N/A
6/30/2013	9	3	N/A	2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CDXは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.3% ) よりも高い成長率であると考えられます。

収益対市場: CDX今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: CDX今後 3 年以内に収益を上げることが予想されます。

収益対市場: CDXの収益 ( 63.7% ) Australian市場 ( 5.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: CDXの収益 ( 63.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CDXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

CardieX 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Recent updates

New major risk - Market cap size

Less than half of directors are independent

CardieX Limited Appoints Charlie Taylor as an Independent Non-Executive Director, Effective 1 March 2024

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

CardieX Limited has filed a Follow-on Equity Offering in the amount of AUD 7.62 million.

CardieX Limited, Annual General Meeting, Nov 30, 2023

CardieX Limited Announces Resignation of Lesa Musatto as Independent Non-Executive Director

Full year 2023 earnings released: AU$0.15 loss per share (vs AU$0.12 loss in FY 2022)

New minor risk - Financial data availability

CardieX Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

CardieX Limited announced that it expects to receive AUD 2.3 million in funding

First half 2023 earnings released: AU$0.072 loss per share (vs AU$0.053 loss in 1H 2022)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.044413 million.

CardieX Limited Appoints Reid Yeoman as the Group's New Us Based Chief Financial Officer

CardieX Limited (ASX:CDX) acquired All the Assets of Blumio, Inc.

Less than half of directors are independent

CardieX Limited, Annual General Meeting, Nov 30, 2022

CardieX Limited Auditor Raises 'Going Concern' Doubt

Full year 2022 earnings released: AU$0.12 loss per share (vs AU$0.059 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.

Full year 2022 earnings released: AU$0.11 loss per share (vs AU$0.064 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.330001 million.

CardieX Limited Announces FDA 510(K) Submission for Conneqt Pulse Dual Blood Pressure and Arterial Health Monitor

FDA Update for CONNEQT Companion App of Cardiex Limited

CardieX Limited Announces Appointment of Lesa Musatto as an Independent, Non-Executive Director

Less than half of directors are independent

CardieX Submits FDA Application for its CONNEQT App

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Global Health Technology Company CardieX and Mobvoi Launch a Revolutionary Heart Health Monitoring Smartwatch for Consumers

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

CardieX Launches CONNEQT™

What Can We Learn About CardieX's (ASX:CDX) CEO Compensation?

Shareholders Are Thrilled That The CardieX (ASX:CDX) Share Price Increased 169%

CardieX Limited Announces New Devices on Track for Launch in 2021

CardieX Limited Announces Executive Appointments

Have Insiders Been Buying CardieX Limited (ASX:CDX) Shares?

CardieX Limited, Annual General Meeting, Dec 11, 2020

CardieX Limited Limited Announces Commercial Partnership Agreement with Mobvoi for New Health Smartwatch

Full year earnings released - AU$0.0046 loss per share

Full year earnings released - AU$0.0046 loss per share

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘